Internal and Emergency Medicine

, Volume 2, Issue 2, pp 107–112 | Cite as

A young man with persistent eosinophilia

Case Record


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hardy WR, Anderson RE (1968) The hypereosinophilic syndromes. Ann Intern Med 68:1220–1229PubMedGoogle Scholar
  2. 2.
    Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 54:1–27PubMedCrossRefGoogle Scholar
  3. 3.
    Gotlib J, Cools J, Malone JM III et al (2004) The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103:2879–2891PubMedCrossRefGoogle Scholar
  4. 4.
    Roujeau JC (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209:123–129PubMedCrossRefGoogle Scholar
  5. 5.
    Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492PubMedCrossRefGoogle Scholar
  6. 6.
    Leder K, Weller PF (2000) Eosinophilia and helminthic infections. Baillieres Best Pract Res Clin Haematol 13:301–317PubMedCrossRefGoogle Scholar
  7. 7.
    Soubani AO, Chandrasekar PH (2002) The clinical spectrum of pulmonary aspergillosis. Chest 121:1988–1999PubMedCrossRefGoogle Scholar
  8. 8.
    Thomeer M, Moerman P, Westhovens R et al (1999) Systemic lupus erythematosus, eosinophilia and Loeffler’s endocarditis. An unusual association. Eur Respir J 13:930–933PubMedCrossRefGoogle Scholar
  9. 9.
    Kawasaki A, Mizushima Y, Matsui S et al (1991) A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report. Tumori 77:527–530PubMedGoogle Scholar
  10. 10.
    Endo M, Usuki K, Kitazume K et al (1995) Hypereosinophilic syndrome in Hodgkin’s disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 71:313–314PubMedGoogle Scholar
  11. 11.
    Catovsky D, Bernasconi C, Verdonck PJ et al (1980) The association of eosinophilia with lymphoblastic leukemia and lymphoma: a study of seven patients. Br J Haematol 45:523–534PubMedGoogle Scholar
  12. 12.
    Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83:2759–2779PubMedGoogle Scholar
  13. 13.
    Gleich GJ, Zucker-Franklin D (2003) Eosinophils. In: Zucker-Franklin D, Grossi CE (eds) Atlas of blood cells — function and pathology, 3rd edn. Edi.Ermes, Milan, pp 299–340Google Scholar
  14. 14.
    Forrest DL, Horsman DE, Jensen CL et al (1998) Myelodisplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ 112 hybridization. Cancer Genet Cytogenet 107:65–68PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman JM, Najfeld V, Th’ng KH (1975) Agar culture and chromosome analysis of eosinophilic leukaemia. J Clin Pathol 28:956–961PubMedCrossRefGoogle Scholar
  16. 16.
    Chang HW, Leong KH, Koh DR, Lee SH (1999) Clonality of isolated eosinophils in hypereosinophilic syndrome. Blood 93:1651–1657PubMedGoogle Scholar
  17. 17.
    Luppi M, Marasca R, Morselli M et al (1994) Clonal nature of hypereosinophilic syndrome. Blood 84:349–350PubMedGoogle Scholar
  18. 18.
    Fauci AS, Harley JB, Roberts WC et al (1982) NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97:78–92PubMedGoogle Scholar
  19. 19.
    Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83:2759–2779PubMedGoogle Scholar
  20. 20.
    Ommen SR, Seward JB, Tajik AJ (2000) Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 86:110–113PubMedCrossRefGoogle Scholar
  21. 21.
    Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214PubMedCrossRefGoogle Scholar
  22. 22.
    Gleich GJ, Leiferman KM, Pardanani A et al (2002) Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 359:1577–1578PubMedCrossRefGoogle Scholar
  23. 23.
    Pardanani A, Ketterling RP, Li CY et al (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30:965–970PubMedCrossRefGoogle Scholar
  24. 24.
    Jovanovic JV, Score J, Waghorn K et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood [Epub ahead of print]Google Scholar
  25. 25.
    Klion AD, Law MA, Noel P et al (2004) Safety and efficacy of the monoclonal anti-interleukin 5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103:2939–2941PubMedCrossRefGoogle Scholar
  26. 26.
    Sefcick A, Sowter D, DasGupta E et al (2004) Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 124:558–559PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia Srl 2007

Authors and Affiliations

  1. 1.Department of Clinical and Biological SciencesUniversity of TurinOrbassano, TurinItaly

Personalised recommendations